Here’s What the Wall Street Thinks About Nuvation Bio Inc. (NUVB)

Group 1 - Nuvation Bio Inc. (NYSE:NUVB) is identified as a stock with high potential, currently priced under $10, with a Buy rating reiterated by analysts [1][2] - Analyst Soumit Roy from JonesTrading raised the price target for Nuvation Bio from $10 to $12, citing positive expectations for the upcoming data from the Safusidenib study [1][2] - The success probability for Safusidenib, an IDH1 inhibitor, has been increased from 30% to 50%, with anticipated accelerated approval and launch now expected in 2029 instead of 2030 [2] Group 2 - H.C. Wainwright lowered the price target for Nuvation Bio from $18 to $17 while maintaining a Buy rating, attributing the reduction to lower-than-expected sales for IBTROZI in fiscal Q4 2025 [3] - The sales figure for IBTROZI was reported at $15.7 million, slightly below the firm's expectations of $16.4 million but in line with the consensus of $15.5 million [3] - Consequently, the 2026 sales target for Nuvation Bio was adjusted down from $169.6 million to $163.2 million [3]